{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:10:07Z","timestamp":1788772207486,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.humpath.2026.106217","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:43:45Z","timestamp":1785393825000},"page":"106217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ERBB2 copy number alterations and protein expression in bladder cancer treated by cystectomy"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-6268","authenticated-orcid":false,"given":"John C.","family":"Cheville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael E.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lucien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinav","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Knudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-6955","authenticated-orcid":false,"given":"Sounak","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106217_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systemic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.humpath.2026.106217_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human growth factor receptor 1\/2 positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.humpath.2026.106217_bib3","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Tratuzumab, paclitaxel, carboplatin and gemcitabine in advanced human epidermal growth factor receptor-2 positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106217_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomized phase II trial of gemcitabine + platinum with or without trastuzumab in advanced or metastatic urothelial carcinoma expressing HER2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.humpath.2026.106217_bib5","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally-advanced or metastatic transitional cell carcinoma","volume":"115","author":"Wulfing","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2026.106217_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pan tumor 02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106217_bib7","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2022.40.16_suppl.4518","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.humpath.2026.106217_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106217_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-CO14): a phase IB\/II dose escalation and dose expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106217_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","article-title":"Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma","volume":"88","author":"Chu","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2026.106217_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.04.012","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder- a clinicopathologic and molecular analysis of 52 cases","volume":"148","author":"Zheng","year":"2024","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106217_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106217_bib13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2026.106217_bib14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106217_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2026.106217_bib16","article-title":"Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: an analysis of 99 cases by next generation sequencing","volume":"139","author":"Shen","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2026.106217_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.humpath.2026.106217_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2026.106217_bib19","first-page":"647","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society of for clinical pathology, and American society of clinical oncology","volume":"145","author":"Bartley","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106217_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"issue":"23","key":"10.1016\/j.humpath.2026.106217_bib21","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2 expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.humpath.2026.106217_bib22","first-page":"111","article-title":"Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle invasive bladder cancer: a multicenter real-world study","volume":"10","author":"Guo","year":"2026"},{"issue":"25","key":"10.1016\/j.humpath.2026.106217_bib23","first-page":"2705","article-title":"SGNDV-001: Disitamab vedotin with pembrolizumab in HER2-expressiong locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2026","journal-title":"Future Oncol"},{"key":"10.1016\/j.humpath.2026.106217_bib24","article-title":"Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2026.106217_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in primary tumors","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2026.106217_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4 and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:39:13Z","timestamp":1788770353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0046817726001863"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106217","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERBB2 copy number alterations and protein expression in bladder cancer treated by cystectomy","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106217"}}